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Wolfram syndrome is a rare genetic
spectrum disorder characterized by in-
sulin-dependent diabetes mellitus, op-
tic nerve atrophy, and progressive neu-
rodegeneration, and ranges from mild
to severe clinical symptoms. There is
currently no treatment to delay, halt,
or reverse the progression of Wolfram
syndrome, raising the urgency for inno-
vative therapeutics for this disease.
Here, we summarize our vision for
developing novel treatment strategies
and achieving a cure for Wolfram-syn-
drome-spectrum disorder.
Clinical Manifestations of
Wolfram Syndrome
Wolfram syndrome is a rare, monogenic
life-threatening disease caused largely
by mutations in the WFS1 gene or, in a
small fraction of patients, pathogenic
variants in the CISD2 gene [1]. While in-
sulin-dependent diabetes mellitus, op-
tic nerve atrophy, and neurodegenera-
tion are cardinal features of this
disease, many patients also develop
other symptoms, ranging from hearing
loss and endocrine deficiencies to
neurological and psychiatric conditions
[1]. Accordingly, recent clinical and ge-
netic findings have revealed that
Wolfram syndrome is best character-
ized as a spectrum disorder. Most
Wolfram syndrome patients carry two
recessive pathogenic variants in the
WFS1 gene. The disease begins to
manifest with the clinical onset of insu-
lin-dependent diabetes mellitus at
around age 6 years and optic nerve at-
rophy at age 10 years. Diabetes insipi-
dus, neurogenic bladder, obstructive
sleep apnea, and deafness may also
develop in the next two decades of
life, along with symptoms of brainstem
and cerebellar atrophy, such as
dysphagia, ataxia, and central sleep ap-
nea [1–4]. Some pathogenic variants of
WFS1, particularly dominant variants,
cause deafness or diabetes alone [5,6].
Other dominant WFS1 variants give
rise to deafness and optic nerve atro-
phy or autosomal dominant congenital
cataracts [7,8]. Recently, Dr. Hatters-
ley’s team and ours identified several
dominant de novo WFS1 variants asso-
ciated with a genetic syndrome of
neonatal/infancy-onset diabetes,
congenital sensorineural deafness, and
congenital cataracts [9]. Consequently,
WFS1 is a locus of broad interest to
various disease processes, highlighting
the need for therapeutics targeting the
gene towards potential treatments for
Wolfram-syndrome-spectrum
disorders.
Wolfram syndrome is recognized as a
prototype of endoplasmic reticulum
(ER) disorder [10]. The ER plays a critical
role in the proper folding of secretory
and membrane proteins, calcium ho-
meostasis, and lipid biosynthesis. In
Wolfram syndrome, dysregulation of
calcium homeostasis and misfolding of
pathogenic WFS1 variants causes ER
stress in pancreatic b cells, neurons,
retinal ganglion cells and oligodendro-
cytes, resulting in the dysfunction and
degeneration of affected tissues. ER
dysfunction can also alter mitochon-
drial dynamics, thereby contributing to
neuropsychiatric aspects of this disease
[11]. Wolfram syndrome is thus a sys-
temic disorder caused by ER dysfunc-
tion with no treatments available to
delay, halt, or reverse disease progres-
sion. Nevertheless, numerous avenues
of therapeutic development are
currently under study, heralding the
possibility of new treatments on the ho-
rizon (Figure 1). Below, we discuss the
ongoing efforts on the development
of novel treatments for Wolfram
syndrome.
Chemical Chaperones
A common molecular signature of
Wolfram syndrome is cellular stress
caused by the expression of mutant
Wolfram syndrome 1 (WFS1) proteins
derived from pathogenic WFS1 alleles.
To resolve this, we are testing chemical
chaperones that can optimize the struc-
ture of mutant WFS1 proteins. Chemi-
cal chaperones, such as 4-phenylbutyric
acid and tauroursodeoxycholic acid,
are drugs that are known to mitigate
ER stress by rescuing or stabilizing the
native conformation of mutant WFS1
proteins, thereby reducing protein ag-
gregation and ER stress [12] (Figure 1).
Such designer chemical chaperones
hold the potential to delay Wolfram
syndrome disease progression by
reducing the misfolded WFS1 protein
load in affected cell types, thereby
salvaging remaining tissue function.
ER Calcium Stabilizers
To target calcium dyshomeostasis for
the treatment of Wolfram syndrome,
we are developing and repurposing pu-
tative ER calcium stabilizers. We
recently discovered, for example, that
dantrolene sodium, a US Food and
Drug Administration (FDA)-approved
drug for malignant hyperthermia and
muscle spasm, can act as an ER calcium
stabilizer by targeting ER calcium trans-
porters, specifically ryanodine recep-
tors. Dantrolene sodium can suppress
cell death and dysfunction in neuronal
and b cell mouse models of Wolfram
syndrome, as well as in induced plurip-
otent stem cell (iPSC) models of this dis-
ease [13] (Figure 1). These results
prompted us to initiate an ongoing
phase 1b/2 clinical trial of dantrolene
sodium to assess its safety, tolerability,
and efficacy in pediatric and adult
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patients with Wolfram syndrome (Clin-
ical Trial Number: NCT02829268i).
We are also now developing novel ER
calcium stabilizers tailored for Wolfram
together with the National Center
for Advancing Translational Sciences
(NCATS)ii. These second-generation ER
calcium stabilizers also target ER calcium
transporters, but are intended to be
safer, more potent and have greater
bioavailability to the central nervous sys-
tem and eyes than dantrolene sodium.
Targeting ER Stress
An interestingmolecular target for ther-
apeutic development is p21, which
plays a role in cell proliferation and sur-
vival after ER stress. Valproic acid, a
well-known mood stabilizer, has been
shown to increase the expression of
p21 and confer protection against cell
death in a cell of Wolfram syndrome
[14]. Valproic acid also induces WFS1
expression and modulates the ER stress
response [15]. A phase 2 double-blind,
placebo-controlled drug repurposing
trial is currently underway to evaluate
valproic acid in patients with Wolfram
syndrome (Clinical Trial Number:
NCT03717909).
Glucagon-like peptide (GLP)-1 receptor
agonists are another promising treat-
ment for preventing ER-stress-medi-
ated cell death in Wolfram syndrome.
It has been previously shown that GLP-
1 can suppress apoptosis in cell models
of Wolfram syndrome [13]. Now, data
from two rodent models of Wolfram
syndrome and one patient case report
have confirmed that GLP-1 receptor ag-
onists may improve diabetes in
Wolfram syndrome [16,17]. Further pre-
clinical and clinical studies are needed
to assess the broader efficacy of GLP-
1 agonists in patients with Wolfram
syndrome.
Potential Other Approaches
Recent reports indicate that WFS1 loss
of function is associated with mitochon-
drial dysfunction [11,18]. This likely
stems from ER calcium leakage/ER
stress causing mitochondrial calcium
overload, which results in aberrant or-
ganellar function and decreased ATP
production. In light of these reports,
mitochondrial modulators aimed at
restoring mitochondrial function may
merit further investigation in the
context of Wolfram syndrome, as they
may be able to delay neurodegenera-
tion by reducing neuronal dysfunction.
Gene Therapy
One of the approaches to provide a
cure to Wolframs syndrome could be
via gene therapy. Using adeno-associ-
ated viral (AAV) systems, wild-type
WFS1 could be transferred into the
retinal ganglion cells of patients with
Wolfram syndrome (Figure 1) to supple-
ment the production of correct protein
in the human body. We also envision
using CRISPR/CAS9 gene editing tech-
nology for replacing pathogenic WFS1
Figure 1. Current and Potential Therapeutic Strategies for Wolfram Syndrome.
Schematic shows various pathophysiological steps in development of Wolfram syndrome. The
discussed therapies are shown at the step that they target. Therapies currently in clinical trials and
being developed preclinically are in solid red and dashed blue boxes, respectively. Abbreviations:
AAV, adeno-associated virus; ER, endoplasmic reticulum; GLP-1, glucagon-like peptide 1; iPSC,
induced pluripotent stem cell; WFS1, Wolfram syndrome 1.
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variants with wild-type WFS1 alleles in
Wolfram syndrome patients’ iPSCs and
then create iPSC-derived organoids to
further determine whether this
approach can be used in combination
with regenerative cell-replacement ef-
forts (discussed below).
Regenerative Medicine
Given the deleterious effects of chronic
ER stress on specific cell types in
Wolfram syndrome, there is a need for
regenerative medicine efforts aimed at
replacing these damaged tissues.
More specifically, there is a need for re-
placing pancreatic b cells and retinal
ganglion cells in patients, as defects in
these cell types have the greatest
impact on patients’ quality of life. To
this end, regenerative therapy options
using iPSCs have been developed
[19]. iPSCs from patients with Wolfram
syndrome and their respective siblings
and/or parents have been generated
[13], which could potentially be differ-
entiated into neural progenitor cells,
retinal ganglion cells, oligodendro-
cytes, and pancreatic b cells for thera-
peutic testing and molecular investiga-
tion. These iPSC-derived cell types
may one day be used for cell-based
replacement therapy.
In addition to developing cell-replace-
ment therapeutic strategies, the regen-
erative properties of factors such as
mesencephalic astrocyte-derived neu-
rotrophic factor (MANF), can be tested
on tissues especially sensitive to WFS1
loss of function. MANF has been shown
to activate proliferation of primary islets
and confer protection against ER-
stress-mediated cell death [20]. A ther-
apeutic strategy could be to directly
deliver MANF to neurons, pancreatic b
cells and retinal ganglion cells via AAV
systems, with the goal of suppressing
neurodegeneration and improving b
cell mass, glucose tolerance, and visual
acuity. Further safety and efficacy
studies will be required to optimize de-
livery, minimize adverse effects and
maximize therapeutic benefit.
Concluding Remarks and Future
Perspectives
Wolfram syndrome is a rare genetic dis-
order with more than 200 pathogenic
variants reported in association with
disease. Clinical and genetic heteroge-
neity, as well as variable expressivity,
pose a challenge for designing effec-
tive therapies in this population.
We should therefore aim to design
personalized treatments for Wolfram
syndrome patients in the future.
The first step towards this goal is to
stratify patients based on their ge-
netics. Genetic testing based on next-
generation sequencing (NGS) technol-
ogy, including exome and genome
sequencing, has the ability to do this
by identifying DNA variants that highly
correlate with each patient’s clinical
signs and symptoms. Routine use of
NGS-based genetic testing will not
only facilitate patient counseling by
medical geneticists and genetic coun-
selors, but also serve as a first step to-
wards designing personalized treat-
ments for patients with Wolfram
syndrome.
Notably, although Wolfram syndrome
is an ultra-rare genetic disorder, its con-
stituent medical components (e.g., dia-
betes mellitus, deafness, and retinal
degeneration) and underlying ER path-
ophysiology are not as rare. Conse-
quently, novel treatments designed for
this ultra-rare disorder may have
broader implications for more common
medical conditions related to ER stress
and dysfunction. Thus, by leveraging
the tools and therapeutic efforts target-
ing Wolfram syndrome, we may iden-
tify novel treatment modalities for
more prevalent disorders such as dia-
betes mellitus and neurodegenerative
diseases.
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Spotlight
Interleukin-13 Is
Unlucky for Allergy
Sufferers
Markus M. Xie1
and Alexander L. Dent1,*
Anaphylaxis, a life-threatening allergic
reaction, is dependent on high affinity
allergen-specific IgE. Gowthaman
et al. now show that a new interleukin
(IL)-13-expressing T helper cell subset
specifically promotes high-affinity IgE
responses. The discovery of T follicular
helper (Tfh)13 cells defines potential
new targets for allergy therapies.
The increase in atopic and allergic dis-
eases over the past 30–40 years is of
epidemic proportions and these dis-
eases affect millions of people in the
USA [1,2]. Allergic reactions can lead
to anaphylaxis, a severe and life-threat-
ening form of allergic immune
response. Anaphylaxis is a systemic in-
flammatory response that results in a
dramatic loss of blood pressure and
can lead to organ failure. Food al-
lergies, especially to peanut proteins,
often involve anaphylactic reactions [3].
During the priming phase of an allergic
immune reaction, Interleukin-4 (IL-4) is
produced by T helper (Th) cells that pro-
mote the production of antigen-specific
IgE antibody from B cells. Most IgE then
binds strongly to Fcε receptors on mast
cells. IgE with low affinity for the
allergen protein is not sufficient to fully
activate mast cells and cannot provoke
anaphylaxis in the presence of allergen
(Figure 1A). However, the interaction
of allergen proteins with high-affinity
allergen-specific IgE on the mast cell
surface causes crosslinking of the Fcε
receptors, triggering a signaling
cascade that leads to mast cell degran-
ulation and release of preformed in-
flammatory mediators stored in cyto-
plasmic granules, including histamine,
proteases, cytokines, and chemokines
(Figure 1B) [4]. Release of these inflam-
matory mediators in a systemic
response leads to the severe allergic re-
action of anaphylaxis.
Recent studies have revealed that
specialized IL-4-secreting T follicular
helper (Tfh) cells are essential for the
development of antigen-specific IgE
from activated B cells within a cellular
structure found in lymphoid tissues
called the germinal center [5]. The dis-
covery that Tfh cells control IgE re-
sponses has expanded our knowledge
of mechanisms that control the devel-
opment of allergies. However, a crucial
aspect of the anaphylactic response is
that it is dependent on the develop-
ment of high-affinity IgE specific for
the allergen [6] and despite the clinical
significance of anaphylaxis, the ques-
tion of how high-affinity, allergen-spe-
cific IgE develops in the germinal center
has been unclear. Now, investigators
from Yale University and the Jackson
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